Brain Glioma Diagnosis
Brain Glioma Diagnosis
A glioma is diagnosed in two stages that answer different questions. Imaging shows that a tumour is present, where it is, how large it is, and what surrounds it — and it guides the operation. But imaging cannot name the tumour or give its grade. That comes from examining the tissue, and then from testing the tissue for a small set of molecular markers which, in the adult diffuse gliomas, define the diagnosis itself.
The scan: what MRI shows
MRI is the imaging standard for glioma, and the sequences used answer different questions about the same tumour:
- Contrast-enhanced sequences show where the blood-brain barrier has broken down, which is the part of the tumour that enhances — but not necessarily the whole of it, because infiltrating tumour can be present beyond the enhancing edge.
- T2 and FLAIR sequences show the abnormal tissue and the oedema around it, and are used to judge the extent of the tumour and to plan the operation.
- Perfusion imaging measures blood flow, which helps identify the more active part of a tumour and guides where a biopsy should be taken.
- Spectroscopy measures the chemistry of the tissue, giving additional information when the diagnosis is unclear from the appearance alone.
- A CT scan is used in an emergency and where calcification or bone involvement needs to be seen, but it is not the test used to characterise a glioma.
Why tissue is required
No scan can give the molecular diagnosis, and this is the single most important thing to understand about glioma diagnosis:
- The type is defined by molecular results. Whether an IDH mutation is present, and whether 1p/19q is codeleted, cannot be determined from imaging — yet those two results name the tumour.
- A biopsy is used when removal is not safe. A stereotactic biopsy takes a small sample through a small opening, guided by imaging, and can establish the diagnosis without an operation — though a small sample may not show the whole picture.
- Removal at surgery provides the best tissue. It gives the neuropathologist more material to examine and more certainty about the grade, which is why the operation serves both purposes at once.
- The tissue is examined in several ways — under the microscope, with antibodies that identify cell types, and with molecular tests on the DNA and RNA from the tumour.
- Lumbar puncture is generally avoided at diagnosis, because removing fluid when pressure inside the head is raised carries a risk, and because the diagnosis comes from tissue rather than from the fluid.
The molecular report
The molecular panel is not an optional extra. In the adult diffuse gliomas it is what the diagnosis is built on, and the results also decide which treatments are appropriate:
- IDH1 and IDH2 — the marker that separates the slower-growing gliomas from glioblastoma, and therefore the first result to establish.
- 1p/19q codeletion — the marker that confirms oligodendroglioma, the type in which chemotherapy is combined with radiotherapy rather than used only for recurrence.
- ATRX and TP53 — used to confirm the astrocytoma group when the codeletion result is borderline, because the two types behave differently.
- TERT promoter, EGFR and CDKN2A/B — used to refine the diagnosis and, in an IDH-mutant astrocytoma, a CDKN2A/B deletion is one of the findings that places the tumour at grade 4.
- MGMT promoter methylation — reported before the chemotherapy decision, because it identifies the tumours most likely to benefit from temozolomide.
- H3 K27M and BRAF alterations — requested particularly in children and young adults, where they may define a different tumour or open the possibility of a targeted drug.
How the grade is decided
The grade is a summary of how the tumour is expected to behave, and it is assigned by combining what the tissue looks like with what the molecular tests show:
- Grade 1 — a tumour that forms a defined mass rather than infiltrating, most often in children and young adults, and often treated by surgery alone.
- Grade 2 — an infiltrating tumour without features of active growth; the decision about whether to treat after surgery depends on the molecular type and on how completely it was removed.
- Grade 3 — a tumour showing active growth, for which radiotherapy and chemotherapy usually follow surgery.
- Grade 4 — the most aggressive group, including glioblastoma; in an IDH-mutant astrocytoma, a CDKN2A/B deletion is enough to place it here even without the features that used to define the grade.
- The grade is only part of the answer. The type, the site, the extent of removal and the patient's condition all influence what is recommended, and the grade alone does not determine it.
Planning an operation near critical areas
When a tumour lies close to the parts of the brain that control speech, movement or vision, the assessment before surgery matters as much as the operation itself:
- Functional MRI shows which areas of cortex are active during a task such as moving a hand or generating words, and maps them relative to the tumour.
- Diffusion tractography images the white matter tracts that carry signals between regions, so that the pathways to be preserved can be identified in advance.
- Neuropsychological assessment records the function present before treatment, so that any change afterwards can be attributed accurately rather than assumed.
- Awake craniotomy allows the surgeon to test speech or movement while the patient is awake and cooperating, which is how function is protected when the tumour is within or beside an eloquent area.
- Intraoperative imaging and fluorescence help judge the extent of removal during the operation, and the scan taken afterwards records the result objectively.
Turning the results into a written plan
Because glioma treatment is a sequence, the plan that follows diagnosis should state its own decision points:
- The full diagnosis, not a name — the tumour type with its molecular profile, the grade and the reason for it. In this disease the diagnosis is a set of results, and the report itself should be requested.
- The extent of removal — the operative report together with the postoperative scan, and a statement of how much tumour remains.
- What treatment follows, and why — whether radiotherapy is planned, whether it is combined with chemotherapy, and which molecular result decided that.
- The schedule for the next phase — the radiotherapy plan with dose and target, and the monitoring interval that will follow it, with what change would prompt an earlier scan.
- Rehabilitation and function — physiotherapy, speech therapy and cognitive support arranged from the start rather than after treatment, because they determine how much function is recovered.
- Fertility and family planning where relevant, discussed before treatment rather than after it.